JPMorgan raised the firm’s price target on Oculis (OCS) to $42 from $38 and keeps an Overweight rating on the shares. The firm expects topline results in a joint disclosure from Oculis’s two Phase 3 clinical trials evaluating its lead asset OCS-01 for the treatment of diabetic macular edema in June. The company offers ‘multiple shots on goals with attractive potential market opportunities,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
- Oculis price target raised to $47 from $44 at H.C. Wainwright
- Oculis price target raised to $44 from $43 at BofA
- Oculis reports Q1 EPS (49c), consensus (41c)
- Oculis Reports Strong Liquidity in Q1 2026 Unaudited Results